Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Megestrol Acetate with EDP-M in Advanced Adrenocortical Carcinoma
NCT05913427Phase 2Recruiting
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Jun 2022
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in adrenocortical carcinoma (ACC) comparing EDP-M + Megestrol Acetate with EDP-M + Placebo (2 arms). Primary endpoint: Evaluation of the activity of the combination regimen at 18 months. Started Jun 2022; status: recruiting.
02
Drugs
megestrol
03
Conditions
adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT05913427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05913427.